Status:
COMPLETED
Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help...
Detailed Description
OBJECTIVES: * To validate the mass spectrometry profile that is predictive of survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with EGFR inhibit...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of recurrent or metastatic head and neck squamous cell carcinoma
- Meets 1 of the following criteria:
- Enrolled on clinical trial ECOG-E3301 and previously treated with irinotecan hydrochloride and docetaxel
- Enrolled on clinical trial VU-VICC-HN-0501 and previously treated with docetaxel and bortezomib
- Plasma and serum samples available for analysis
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
July 8 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 8 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00898911
Start Date
July 8 2008
End Date
April 8 2012
Last Update
May 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.